Stock Events

Stock Events

Incyte

$117.41

203

-$0.18-0.15%Friday 08:26

Statistics

Day High

118.24

Day Low

117.41

52W High

123.69

52W Low

92.23

Volume

70

Avg. Volume

-

Mkt Cap

23.93B

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

Feb 9Expected

Q3 2025

Q4 2025

Q1 2026

Q2 2026

Q3 2026

Next

-3.93

-1.59

0.75

3.09

Expected EPS

1.906924

Actual EPS

N/A

Financials

25.03%Profit Margin

Profitable

2020

2021

2022

2023

2024

2025

5.14BRevenue

1.29BNet Income

Analyst Ratings

$132.58Average Price Target

The highest estimate is ⁦157.00⁩.
From 19 ratings within the last 6 months. This is not an investment recommendation.

Buy

53%

Hold

47%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INCY.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Amgen competes with Incyte in the biopharmaceutical sector, focusing on innovative therapeutics in areas overlapping with Incyte's interests, such as oncology and inflammation.

Gilead Sciences

Gilead Sciences operates in similar therapeutic areas as Incyte, including oncology and antiviral drugs, making them direct competitors in the market for cancer and other treatments.

Bristol-Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that competes with Incyte in the development of cancer treatments and immunotherapies, areas where Incyte is also heavily invested.

Merck is a leading pharmaceutical company that competes with Incyte in the oncology sector, particularly in the development and marketing of cancer treatments.

Novartis competes with Incyte in multiple areas, including oncology and autoimmune diseases, with a broad portfolio that overlaps with Incyte's research and development focus.

Pfizer is a global pharmaceutical giant that competes with Incyte in the development of drugs for various diseases, including cancer, which is a key focus area for Incyte.

Roche Holding AG competes with Incyte in the oncology and hematology fields, with a strong focus on developing innovative cancer treatments.

AbbVie competes with Incyte in the area of immunology and oncology, particularly in the development of treatments for cancers and autoimmune diseases.

Eli Lilly and Company competes with Incyte in the pharmaceutical sector, focusing on areas such as oncology, which is a significant part of Incyte's business.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a competitor in the biopharmaceutical field, focusing on innovative treatments in areas like oncology and inflammatory diseases, directly competing with Incyte's research and product offerings.

About

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Show More

CEO

ISIN

US45337C1027

Listings

0 Comments

Share your thoughts

FAQs

What is Incyte stock price today?▼

The current price of INCY.BOATS is $117.41 USD — it has decreased by -0.15% in the past 24 hours. Watch Incyte stock price performance more closely on the chart.

What is Incyte stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Incyte stocks are traded under the ticker INCY.BOATS.

What is Incyte market cap?▼

Today Incyte has the market capitalization of 23.93B

When is the next Incyte earnings date?▼

Incyte is going to release the next earnings report on February 9, 2027.

What were Incyte earnings last quarter?▼

INCY.BOATS earnings for the last quarter are -3.6 USD per share, whereas the estimation was -3.93 USD resulting in a +8.49% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is Incyte revenue for the last year?▼

Incyte revenue for the last year amounts to 5.14B USD.

What is Incyte net income for the last year?▼

INCY.BOATS net income for the last year is 1.29B USD.

In which sector is Incyte located?▼

Incyte operates in the Other sector.

When did Incyte complete a stock split?▼

Incyte has not had any recent stock splits.